/BMRN
BioMarin Pharmaceutical Inc.
BMRN • NASDAQBMRN • NASDAQ • Healthcare
$58.90-0.29%-0.17
$58.90-0.29%(-0.17)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
100Low Risk
Momentum
55Neutral
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
77.1%▼2.5pp
Revenue after COGS
Operating
16.6%▼0.4pp
After operating expenses
Net
10.8%▼4.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
32.7
Price vs earnings
EV/EBITDA
18.7
Enterprise value
FCF Yield
6.4%
Cash generation
Earnings Yield
3.1%
Inverse of P/E
Capital Efficiency
5
GoAI Quality ScoreWeak
ROEReturn on Equity
5.7%Fair
ROAReturn on Assets
4.6%Fair
ROICReturn on Invested Capital
5.6%Fair
Financial Health
Current RatioHealthy
5.21
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-1.17x
Debt repayment capacity (<3x)
Income QualityStrong
2.37
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Gross Profit | $2.48B | $2.27B | $1.89B | $1.59B | $1.38B |
| Gross Margin | 77.1% | 79.7% | 78.0% | 76.0% | 74.5% |
| Operating Income | $533.48M | $484.21M | $185.77M | $160.97M | -$82.34M |
| Net Income | $348.90M | $426.86M | $167.65M | $141.56M | -$64.08M |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% |
| EPS | $1.82 | $2.25 | $0.89 | $0.76 | -$0.35 |
Average Price Target
$86.60▲ 47.0% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical Inc., the average price target is $86.60, with a high forecast of $105.00 and a low forecast of $60.00. The average price target represents a 47.0% increase from the current price of $58.90.
Highest
$105.00
Average
$86.60
Lowest
$60.00
Rating Distribution
Strong Buy
0
0%
Buy
27
68%
Hold
13
33%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
B of A Securities● Maintain
Buy
2026-03-11Barclays● Maintain
Overweight
2026-03-04HC Wainwright & Co.● Maintain
Neutral
2026-03-02Canaccord Genuity● Maintain
Buy
2026-02-26HC Wainwright & Co.● Maintain
Neutral
2026-02-25Bernstein● Maintain
Outperform
2026-02-25Guggenheim● Maintain
Buy
2026-02-25Oppenheimer● Maintain
Outperform
2026-02-24Wells Fargo● Maintain
Overweight
2026-02-18Piper Sandler● Maintain
Overweight
2026-02-06Earnings History & Surprises
BEAT RATE
94%
Last 18 quarters
AVG SURPRISE
+92.8%
EPS vs Estimate
BEATS / MISSES
17/0
1 met exactly
LATEST EPS
$0.46
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+171.5%
$0.46 vs $0.17
Q4 '25
+180.0%
$0.12 vs $-0.15
Q3 '25
+67.2%
$1.44 vs $0.86
Q2 '25
+20.2%
$1.13 vs $0.94
Q1 '25
+70.4%
$0.92 vs $0.54
Q4 '24
+16.7%
$0.91 vs $0.78
Q3 '24
+168.3%
$0.96 vs $0.36
Q2 '24
+127.7%
$0.71 vs $0.31
Q1 '24
+11.4%
$0.49 vs $0.44
Q4 '23
$0.46 vs $0.46
Q3 '23
+14.9%
$0.54 vs $0.47
Q2 '23
+39.5%
$0.60 vs $0.43
No investor questions available.
Latest News
No news available